Compare Adaptive Biotechnologies Corp (ADPT) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs PepsiCo, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while PepsiCo, Inc. trades at $142.72 (market cap $198.15B). The key difference: PepsiCo, Inc. is far larger — about 59.5× Adaptive Biotechnologies Corp's market cap, and PepsiCo, Inc. pays a 4.08% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | PEP | |
|---|---|---|
Market Cap | $3.33B | $198.15B |
Sector | Health | Consumer Staples |
52-Week High | $22.37 | $170.44 |
52-Week Low | $10.24 | $133.81 |
Enterprise Value | $3.19B | $240.05B |
Dividend Yield | — | 4.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
PepsiCo (PEP) trades at $142.50, down 0.55% on the day, with a bullish technical signal despite bearish moving averages. The company maintains strong fundamentals with $93.93B revenue and consistent earnings beats, though net income margin declined to 8.77% in 2025. Recent news highlights price adjustments for snacks after consumer pushback on high prices, while analysts expect in-line Q1 2026 results.
PEP offers stable investment appeal with 34% analyst buy ratings and $161.73 consensus target, representing 13% upside. Risks include pricing sensitivity in North America and competitive pressures, but strong cash flow generation and dividend payments provide shareholder value support. The stock presents a balanced opportunity for income-focused investors seeking consumer staples exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
